Cohort Study of Intrauterine Diseases

NCT07048327 | Recruiting DMC

• 1 other identifier: CSID
• Study Type: observational
• Target: 2,000
• Locations: 1 country
• Sites: 1

Brief Summary

"This study employs a prospective cohort design by establishing a uterine cavity diseases research platform. The investigators will collect participants' current medical history, menstrual and obstetric history, past medical history, physical and gynecological examinations, imaging studies, laboratory tests, and pathological examinations. After the hysteroscopic surgery, the investigators will conduct a one-year follow-up on the disease progression of the participants. Through this comprehensive approach, the investigators aim to deeply investigate the pathogenesis, risk factors, and optimized treatment strategies for uterine cavity diseases."

Conditions

Endometrial Cancer; Endometrial Hyperplasia; Endometrial Polyps

Keywords

Intrauterine diseases; Endometrial Cancer; Endometrial Hyperplasia; Endometrial Polyps; Cohort Study

Outcome Measures

Primary Outcomes (1)

• The recurrence of endometrial polyps or endometrial hyperplasia.

  To evaluate the presence of disease progression and recurrence through imaging results.

  Follow up every three months for one year after hysteroscopic surgery

Study Arms (1)

Intrauterine Diseases Cohort

Disease-specific cohort for uterine cavity diseases

Other: No intervention (observational study)

Interventions

No intervention (observational study) OTHER

No intervention (observational study)

Intrauterine Diseases Cohort

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Study Population will be enrolled by a multicenter study led by Tongji Hospital , in collaboration with over 30 tertiary hospitals. Patients requiring hysteroscopic or curettage procedures for intrauterine lesions such as endometrial hyperplasia, polyps, and malignancies will be recruited.

You may qualify if:

• Age: 18-80 years;
• Patients requiring hysteroscopy or diagnostic curettage for intrauterine pathologies (e.g., endometrial hyperplasia, endometrial polyps, submucosal uterine fibroids, adenomyosis, or endometrial malignancies);
• Willing and able to comply with follow-up requirements;
• Signed informed consent obtained.

You may not qualify if:

• Concurrent participation in other drug clinical trials;
• Contraindications to or inability to tolerate hysteroscopy/curettage procedures;
• Unwilling or unable to provide informed consent;
• Unwilling or unable to adhere to study protocols.

Sponsors & Collaborators

• Wenwen Wang: lead

Study Sites (1)

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430000, China

RECRUITING

MeSH Terms

Conditions

Endometrial Neoplasms; Endometrial Hyperplasia

Interventions

Observation

Condition Hierarchy (Ancestors)

Uterine Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Uterine Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases

Intervention Hierarchy (Ancestors)

Methods; Investigative Techniques

Central Study Contacts

Wen W Wang, Dr.

CONTACT

+86 15927167698; petrawang@163.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Clinical Professor

Study Record Dates

• First Submitted: June 19, 2025
• First Posted: July 2, 2025
• Study Start: July 1, 2025
• Primary Completion (Estimated): July 1, 2028
• Study Completion (Estimated): July 1, 2028
• Last Updated: July 2, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)